Focus: Bracco is a specialized imaging company headquartered in Milan, Italy, with 1,000–5,000 employees focused on contrast agents and diagnostic imaging solutions. Founded in 1927, it serves cardiovascular, gastroenterology, and hematology markets globally.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Bracco to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Bracco's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Legacy product nearing end-of-life; represents ongoing revenuebase but limited growth potential.
Help build intelligence for Bracco
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Only actively growing product in portfolio; LOE not until 2029 provides 3+ year revenue window.
Established MRI contrast workhorse but facing patent expiration and generic competition.
Legacy iodinated contrast agent nearing end-of-life.
Historic renal imaging product in declining phase.
Mature GI contrast formulation with stable market position.
Established barium sulfate product maintaining steady clinical adoption.
Key X-ray contrast with LOE expected October 2028; generic erosion imminent.
Legacy oral contrast agent approaching end-of-life.
Nuclear imaging agent for biliary function with declining utilization as imaging modalities evolve.
41 discontinued, 23 duplicate formulations not shown
Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System - BioSpace
Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System BioSpace
Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System - PR Newswire
Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System PR Newswire
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT - STT Info
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT STT Info
Bracco Imaging and NYU Langone Health Announce Strategic Alliance Agreement to Advance Medical Imaging Innovation - PA Media
Bracco Imaging and NYU Langone Health Announce Strategic Alliance Agreement to Advance Medical Imaging Innovation PA Media
Bracco Imaging and NYU Langone Health Announce Strategic Alliance Agreement to Advance Medical Imaging Innovation - PR Newswire
Bracco Imaging and NYU Langone Health Announce Strategic Alliance Agreement to Advance Medical Imaging Innovation PR Newswire
8-K Filing: Ionetix Corp / DE / (CIK 0002108121) — CURRENT REPORT
CURRENT REPORT
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo